Abstract
(Am J Obstet Gynecol. 2021;225:666.e1–15) Preeclampsia affects up to 8% of pregnancies and is associated with maternal and neonatal morbidities. Preeclampsia also shares characteristics with other cardiovascular diseases. Pravastatin has been considered a possible method of preventing preeclampsia, supported by preclinical studies and pilot clinical studies using 10 mg pravastatin in high-risk patients. This study aimed to determine the safety and pharmacokinetic parameters of 20 mg pravastatin in patients with a high risk of preeclampsia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
